AXLA — Axcella Health Share News
0.000.00%
Last trade - 00:00Axcella Therapeutics up on promising data of NASH drug
Brief: Axcella Announces Positive Interim Data From Phase 2B Emmpact Study Of AXA1125 In NASH
Brief: Axcella Announces Interim Data From Phase 2b Emmpact Study Of Axa1125 In Nonalcoholic Steatohepatitis (Nash)
Brief: Axcella Reports Second Quarter Financial Results And Provides Business Update
U.S. STOCKS ON THE MOVE-Repligen, Tesla, Harmony Biosciences
U.S. STOCKS ON THE MOVE-Arista Networks, Innoviz, JetBlue
U.S. STOCKS ON THE MOVE-Cowen, Pinterest, Uber
Axcella gains as long COVID treatment helps some patients in small trial
Brief: Axcella Announces Highly Promising Results From Phase 2a Placebo Controlled Clinical Trial For Long COVID
Brief: Axcella Announces Results From Phase 2a Placebo Controlled Clinical Trial For Long Covid Subjects
Axcella long COVID treatment helps some patients in small trial
Axcella Health Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Axcella Reports First Quarter Financial Results And Provides Business Update
Axcella Health Inc expected to post a loss of 39 cents a share - Earnings Preview
Axcella Health Inc reports results for the quarter ended in December - Earnings Summary
Brief: Axcella Posts Quarterly Net Loss Per Share $0.46
Axcella Health Inc expected to post a loss of 44 cents a share - Earnings Preview
Brief: Axcella Therapeutics Announces $25 Million Registered Direct Offering Of Common Stock Priced At The Market
Axcella Health Inc expected to post a loss of 44 cents a share - Earnings Preview